Study shows PromarkerD ability to also predict late-stage kidney decline in type-2 diabetes patients
The Company is pleased to announce the results of a study demonstrating the potential ability of...
World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years
Independent consultant Boston Healthcare Associates modelled the budget impact of using PromarkerD compared to the current standard of care, to proactively test for diabetic kidney disease in patients with type 2 diabetes but who otherwise have no sign of kidney disease. It found the test — developed by Proteomics International — could result in net savings to Medicare and commercial insurers of USD384 billion over 10 years.
The company presented this data as a poster abstract at the American Diabetes Association’s 81st Scientific Sessions.